Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) is advancing a novel approach to cancer treatment that could have significant implications for patients with limited options. In a recent interview on the IBN BioMedWire Podcast, Chief Medical Officer Dr. Islam Mohamed detailed the company's lead drug candidate, ONC010, which targets the DNA repair enzyme polynucleotide kinase phosphatase (PNKP). The discussion, disseminated on behalf of Onco-Innovations, sheds light on a potential first-in-human clinical program and the science behind the drug.
Mohamed emphasized two selectivity mechanisms that distinguish ONC010 from conventional therapies. The first, synthetic lethality, is designed to limit the drug's lethality to cancer cells that have lost PTEN or SHP-1, two tumor suppressor genes commonly mutated in various cancers. This approach aims to spare healthy cells while attacking tumors with specific genetic vulnerabilities. The second mechanism involves nanoparticle delivery, which is intended to concentrate the drug within tumor tissue, potentially enhancing efficacy and reducing systemic toxicity.
Preclinical research conducted at the University of Alberta provides early support for these mechanisms. According to Mohamed, the nano-formulated PNKP inhibitor demonstrated single-agent antitumor activity, was tolerated at tested doses, and prolonged survival relative to controls. These findings are crucial as they suggest ONC010 could be effective as a standalone treatment, a rare attribute in oncology where combination therapies are often required.
The importance of this announcement lies in its potential to address unmet needs in cancer treatment. PNKP is a novel clinical target in the DNA damage response pathway, and Onco-Innovations holds an exclusive worldwide license to patented technology directed to its therapeutic inhibition. By focusing on PNKP, the company is exploring a new avenue that could complement existing treatments or offer alternatives for patients who have become resistant to other therapies. The synthetic lethality approach is particularly promising because it exploits specific genetic defects in cancer cells, potentially leading to more personalized and effective treatments.
Furthermore, the nanoparticle delivery system represents a cutting-edge method to improve drug targeting. If successful in human trials, this could reduce side effects and improve patient outcomes. The planned first-in-human clinical program is a critical next step, and its progress will be closely watched by investors and the medical community alike.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, with a mission to pursue prevention and treatment through pioneering research. The company's focus on PNKP inhibition positions it at the forefront of DNA damage response therapies, a rapidly evolving field in oncology.
For those interested in learning more, the full press release is available at https://ibn.fm/XgpMR. Additionally, the latest news and updates relating to ONNVF can be found in the company's newsroom at https://ibn.fm/ONNVF. BioMedWire, a specialized communications platform focused on biotechnology and life sciences, disseminated the podcast. More information about BioMedWire is available at https://www.BioMedWire.com.
The implications of Onco-Innovations' work extend beyond a single drug candidate. If ONC010 proves successful in clinical trials, it could validate PNKP as a target and open doors for additional therapies. Moreover, the synthetic lethality and nanoparticle delivery strategies could be applied to other cancers, potentially leading to a new class of targeted treatments. As the company moves toward first-in-human studies, the oncology community will be watching closely, as success could represent a meaningful step forward in the fight against cancer.
